Search

everythinglearnresearchcommunity

for

Search:↓

Being obese and eating too many calories may increase the risk of kidney cancer, but physical activity doesn't seem to affect this risk.

Kidney cancer cells without folliculin are more sensitive to radiation due to increased self-eating cell death.

Alopecia areata patients have varied cancer risks, with some cancers being lower and others higher.

Birt–Hogg–Dubé syndrome is a rare genetic condition causing skin lesions, lung cysts, and a higher chance of kidney cancer.

A man with kidney tumors and lung cysts was diagnosed with Birt–Hogg–Dubé syndrome and treated successfully, with genetic testing confirming the diagnosis.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.

ATP-sensitive K+ channel subunits, particularly Sur2A, play a significant role in various cancers.

Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.

Disrupting the Flcn gene in mice causes early kidney cysts and tumors, which can be treated with rapamycin.

The tumor suppressor gene FLCN affects mitochondrial function and energy use in cells.

New findings suggest the protein linked to Birt–Hogg–Dubé syndrome is important in cell signaling and could affect treatment understanding.

CRTH2 antagonists might be useful for treating many conditions because they play a role in immune and inflammation responses.

Early detection of specific skin lesions can help identify Birt-Hogg-Dube syndrome and prevent serious complications.

Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.

New therapies for Birt–Hogg–Dubé syndrome are being developed based on understanding the FLCN gene's role.

Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.

Targeting colon cancer stem cells might lead to better treatment results.

Cancer rates are increasing in developed countries, with estrogen, aging, low vitamin D3, and HPV infection as common causes.

Chemotherapy in children often causes hair loss, nausea, vomiting, and mood swings.

A group has developed therapies that show promise for treating cancer and various other conditions.

A cancer patient's hair became permanently curly after treatment with nivolumab.

High levels of ST14 and TMEFF1 proteins in ovarian cancer are linked to worse patient outcomes and may be a new treatment target.

Long-term diabetes is linked to lower prostate cancer risk.

Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Some cancer and immune system drugs can cause serious side effects, including heart, lung, nerve, and organ damage, which need careful monitoring and management.

Ozone therapy might improve cancer treatment and reduce its side effects.